Cargando…

New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview

Non-infectious uveitis (NIU) is a group of disorders characterized by intraocular inflammation at different levels of the eye. NIU is a leading cause of irreversible blindness in working-age population in the developed world. The goal of uveitis treatment is to control inflammation, prevent recurren...

Descripción completa

Detalles Bibliográficos
Autores principales: Valenzuela, Rodrigo A., Flores, Iván, Urrutia, Beatriz, Fuentes, Francisca, Sabat, Pablo E., Llanos, Carolina, Cuitino, Loreto, Urzua, Cristhian A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250389/
https://www.ncbi.nlm.nih.gov/pubmed/32508634
http://dx.doi.org/10.3389/fphar.2020.00655
_version_ 1783538753535475712
author Valenzuela, Rodrigo A.
Flores, Iván
Urrutia, Beatriz
Fuentes, Francisca
Sabat, Pablo E.
Llanos, Carolina
Cuitino, Loreto
Urzua, Cristhian A.
author_facet Valenzuela, Rodrigo A.
Flores, Iván
Urrutia, Beatriz
Fuentes, Francisca
Sabat, Pablo E.
Llanos, Carolina
Cuitino, Loreto
Urzua, Cristhian A.
author_sort Valenzuela, Rodrigo A.
collection PubMed
description Non-infectious uveitis (NIU) is a group of disorders characterized by intraocular inflammation at different levels of the eye. NIU is a leading cause of irreversible blindness in working-age population in the developed world. The goal of uveitis treatment is to control inflammation, prevent recurrences, and preserve vision, as well as minimize the adverse effects of medications. Currently, the standard of care for NIU includes the administration of corticosteroids (CS) as first-line agents, but in some cases a more aggressive therapy is required. This includes synthetic immunosuppressants, such as antimetabolites (methotrexate, mycophenolate mofetil, and azathioprine), calcineurinic inhibitors (cyclosporine, tacrolimus), and alkylating agents (cyclophosphamide, chlorambucil). In those patients who become intolerant or refractory to CS and conventional immunosuppressive treatment, biologic agents have arisen as an effective therapy. Among the most evaluated treatments, TNF-α inhibitors, IL blockers, and anti-CD20 therapy have emerged. In this regard, anti-TNF agents (infliximab and adalimumab) have shown the strongest results in terms of favorable outcomes. In this review, we discuss latest evidence concerning to the effectiveness of biologic therapy, and present new therapeutic approaches directed against immune components as potential novel therapies for NIU.
format Online
Article
Text
id pubmed-7250389
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-72503892020-06-05 New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview Valenzuela, Rodrigo A. Flores, Iván Urrutia, Beatriz Fuentes, Francisca Sabat, Pablo E. Llanos, Carolina Cuitino, Loreto Urzua, Cristhian A. Front Pharmacol Pharmacology Non-infectious uveitis (NIU) is a group of disorders characterized by intraocular inflammation at different levels of the eye. NIU is a leading cause of irreversible blindness in working-age population in the developed world. The goal of uveitis treatment is to control inflammation, prevent recurrences, and preserve vision, as well as minimize the adverse effects of medications. Currently, the standard of care for NIU includes the administration of corticosteroids (CS) as first-line agents, but in some cases a more aggressive therapy is required. This includes synthetic immunosuppressants, such as antimetabolites (methotrexate, mycophenolate mofetil, and azathioprine), calcineurinic inhibitors (cyclosporine, tacrolimus), and alkylating agents (cyclophosphamide, chlorambucil). In those patients who become intolerant or refractory to CS and conventional immunosuppressive treatment, biologic agents have arisen as an effective therapy. Among the most evaluated treatments, TNF-α inhibitors, IL blockers, and anti-CD20 therapy have emerged. In this regard, anti-TNF agents (infliximab and adalimumab) have shown the strongest results in terms of favorable outcomes. In this review, we discuss latest evidence concerning to the effectiveness of biologic therapy, and present new therapeutic approaches directed against immune components as potential novel therapies for NIU. Frontiers Media S.A. 2020-05-08 /pmc/articles/PMC7250389/ /pubmed/32508634 http://dx.doi.org/10.3389/fphar.2020.00655 Text en Copyright © 2020 Valenzuela, Flores, Urrutia, Fuentes, Sabat, Llanos, Cuitino and Urzua http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Valenzuela, Rodrigo A.
Flores, Iván
Urrutia, Beatriz
Fuentes, Francisca
Sabat, Pablo E.
Llanos, Carolina
Cuitino, Loreto
Urzua, Cristhian A.
New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview
title New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview
title_full New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview
title_fullStr New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview
title_full_unstemmed New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview
title_short New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview
title_sort new pharmacological strategies for the treatment of non-infectious uveitis. a minireview
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250389/
https://www.ncbi.nlm.nih.gov/pubmed/32508634
http://dx.doi.org/10.3389/fphar.2020.00655
work_keys_str_mv AT valenzuelarodrigoa newpharmacologicalstrategiesforthetreatmentofnoninfectiousuveitisaminireview
AT floresivan newpharmacologicalstrategiesforthetreatmentofnoninfectiousuveitisaminireview
AT urrutiabeatriz newpharmacologicalstrategiesforthetreatmentofnoninfectiousuveitisaminireview
AT fuentesfrancisca newpharmacologicalstrategiesforthetreatmentofnoninfectiousuveitisaminireview
AT sabatpabloe newpharmacologicalstrategiesforthetreatmentofnoninfectiousuveitisaminireview
AT llanoscarolina newpharmacologicalstrategiesforthetreatmentofnoninfectiousuveitisaminireview
AT cuitinoloreto newpharmacologicalstrategiesforthetreatmentofnoninfectiousuveitisaminireview
AT urzuacristhiana newpharmacologicalstrategiesforthetreatmentofnoninfectiousuveitisaminireview